Ryan O’Keefe: Diagnostic Insights Into High-Risk Myelodysplastic Syndrome
Ryan O’Keefe, Internal Medicine Resident at the Hospital of The University of Pennsylvania, Creator of Point of Care Medicine, shared a post on X:
“Daily Pearl(s):
High-Risk Myelodysplastic Syndrome (MDS) with U2AF1 Mutation.
The triad of unexplained systemic inflammation (high ESR/CRP), progressive cytopenias, and an opportunistic infection (such as candida esophagitis) should raise suspicion for an underlying hematologic malignancy like MDS.
In complex cases with multiple problems, systematically evaluate each one before attempting to unify them – pursuing a red herring as part of a systemic process can be dangerously misleading.
Bilateral adrenal hemorrhage is a medical emergency and can be a rare paraneoplastic manifestation of MDS, which creates a paradoxical state of thrombosis (from inflammation) and hemorrhage (from thrombocytopenia).
Clonal hematopoiesis (MDS, VEXAS syndrome) is an increasingly recognized cause of severe seronegative or atypical autoimmune and vasculitic syndromes, particularly in older adults.
When persistent, unexplained cytopenias and systemic illness remain after extensive infectious and rheumatologic workups, bone marrow biopsy with genetic testing can be a critical diagnostic step.
MDS impairs innate immune function, predisposing patients to opportunistic fungal infections even without classic risk factors like chemotherapy or high-dose steroids.
High-risk MDS is treated with hypomethylating agents (azacitidine) or, in eligible patients, allogeneic stem cell transplantation.
Spliceosome mutations (U2AF1, SF3B1, SRSF2) and UBA1 mutations (VEXAS) are key driver variants to know.
Source: April 11, 2026 Simplicity in Complexity VMR with Jeffrey and Kirtan – dyspnea and vision loss.”
Stay updated with Hemostasis Today.
-
Aug 16, 2026, 13:05Neil Morgan: Submit Your Abstract for BSHT 2027
-
Aug 16, 2026, 12:50Heba Youssef: Can Cefoperazone Cause Coagulopathy?
-
Aug 16, 2026, 12:35Mohammad Alkhalil: Stroke Remains a Dreaded Complication in TAVI
-
Aug 16, 2026, 12:16Jeff Schaffnit: The Power of Community in Rare Blood Disorders
-
Aug 16, 2026, 12:03Fawaz AlOtaibi: Can AI Replace Contrast CTA for Vascular Screening?
-
Aug 16, 2026, 10:31Erhabor Osaro: Critical Issues to Consider During the Clinical Blood Transfusion Process
-
Aug 16, 2026, 10:14Juan Manuel Cisneros Carrasco: The Architects Behind the Blood Donation System
-
Aug 16, 2026, 10:06Honoring the Life and Legacy of Dr. Reed Pyeritz – GADA Canada
-
Aug 16, 2026, 09:51Javier Amador-Castañeda: When a 32 Percent Reduction Tells Only Part of the Story